Human T-cell lymphotropic virus testing of blood donors in Norway: A cost-effect model

International Journal of Epidemiology

Volumn 29, Issue 6, 2000, Pages 1076-1084

  Stigum, Hein ^a   Magnus, Per ^a   Samdal, Helvi Holm ^a   Nord, Erik ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Blooddonors; Cost effect analysis; Cost utility analysis; HIV; HTLV; Mathematical model; Transfusion

Indexed keywords

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD DONOR; BLOOD TRANSFUSION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; EUROPE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; IMMUNOASSAY; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MORTALITY; NONHUMAN; NORWAY; PREVALENCE; PRIORITY JOURNAL; PROGENY; QUALITY OF LIFE; RECIPIENT; RETROVIRUS; SCREENING TEST; SEXUALITY; SPASTIC PARAPLEGIA; T CELL LEUKEMIA; VIRUS TRANSMISSION;

EID: 0034521137     PISSN: 03005771     EISSN: None     Source Type: Journal    
DOI: 10.1093/ije/29.6.1076     Document Type: Article

References (33)

1. Seroepidemiology of the human T-cell leukaemia/lymphoma viruses in Europe. The HTLV European Research Network
2. An HTLV I/II vaccine: From animal model to clinical trials?
3. Human T lymphotropic virus type II (HTLV-II): Epidemiology, molecular properties, and clinical features of infection
4. Male-to-female transmission of human T-cell lymphotropic virus types I and II: Association with viral load. The Retrovirus Epidemiology Donor Study Group
5. The epidemiology of HTLV-I in Europe
6. HTLV examination of Norwegian blood donors
7. Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: Cost effectiveness analysis
8. Production gains from health care: What should be included in cost-effectiveness analysis?
9. Methods for quality adjustment of life years
10. Health status index models for use in resource allocation decisions. A critical review in the light of observed preferences for social choice
11. How Much are Avoided Traffic Accidents Worth to Society? Summary Report
12. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine
13. Recommendations of the Panel on Cost-effectiveness in Health and Medicine
14. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine
15. Tropical spastic paraparesis/HTLV-I-associated myelopathy in Europe and in Africa: Clinical and epidemiologic aspects
16. The potential for spread of HIV in the heterosexual population in Norway: A model study
17. Frequency of sexual partner change in a Norwegian population. Data distribution and covariates
18. The stages of HIV infection: Waiting times and infection transmission probabilities
19. Role of the primary infection in epidemics of HIV infection in gay cohorts
20. Modelling the female-to-male per-act HIV transmission probability in an emerging epidemic in Asia
21. HIV-1 subtypes and male-to-female transmission in Thailand
22. Perninatal transmission: Associated factors and therapeutic approaches
23. Sensitivity and uncertainty analysis of complex models of disease transmission: An HIV model as an example
24. A comparison of three methods for selecting values of input variables in the analysis of output from a computer code
25. Large sample properties of simulations using Latin hypercube sampling
26. S-Plus User's Guide